Ignite Creation Date:
2025-12-24 @ 10:33 PM
Ignite Modification Date:
2026-03-28 @ 11:26 AM
Study NCT ID:
NCT00987935
Status:
COMPLETED
Last Update Posted:
2016-03-10
First Post:
2009-09-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
Sponsor:
Boehringer Ingelheim
Organization:
Study Overview
Official Title:
A Multicenter, Open Label, Phase I/Randomized II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Sorafenib for Advanced Hepatocellular Carcinoma Patients in Asia.
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: